ARTL
Artelo Biosciences·NASDAQ
--
--(--)
--
--(--)
6.14 / 10
Outperform
Sentiment is Outperform (6.14) and fund‑flow score excellent (8.12). Small, medium and large investors show net inflows, though overall and block trends are negative. Analyst consensus is neutral (1 analyst), reinforcing a cautious stance.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
0%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Jason Wesly MccarthyNeutral
Date2025-11-19
InstitutionMaxim Group
Times predicted1
Historical Win Rate100.0%
Is money flowing into or out of ARTL?
- ARTL holds a Bearish analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.14/10 (Outperform).
